Advertisement
UK markets close in 1 hour 58 minutes
  • FTSE 100

    7,832.92
    -44.13 (-0.56%)
     
  • FTSE 250

    19,314.66
    -136.01 (-0.70%)
     
  • AIM

    743.14
    -2.15 (-0.29%)
     
  • GBP/EUR

    1.1680
    -0.0004 (-0.03%)
     
  • GBP/USD

    1.2466
    +0.0028 (+0.22%)
     
  • Bitcoin GBP

    51,861.34
    +1,802.36 (+3.60%)
     
  • CMC Crypto 200

    1,332.10
    +19.47 (+1.48%)
     
  • S&P 500

    5,007.82
    -3.30 (-0.07%)
     
  • DOW

    37,833.01
    +57.63 (+0.15%)
     
  • CRUDE OIL

    82.46
    -0.27 (-0.33%)
     
  • GOLD FUTURES

    2,393.20
    -4.80 (-0.20%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,721.70
    -115.70 (-0.65%)
     
  • CAC 40

    8,011.23
    -12.03 (-0.15%)
     

Russia applies for WHO emergency use tag for its COVID-19 vaccine

FILE PHOTO: Small bottles labeled with "Vaccine" stickers stand near a medical syringe in front of displayed "Coronavirus COVID-19" words in this illustration

(Reuters) - The Russian Direct Investment Fund (RDIF) has submitted applications to the World Health Organization for an Emergency Use Listing and prequalification of its coronavirus vaccine, Sputnik V, Russia's sovereign wealth fund said on Tuesday.

Russia was the first country to grant regulatory approval for a novel coronavirus vaccine, and did so before large-scale trials were complete, stirring concerns among scientists and doctors about the safety and efficacy of the shot.

An Emergency Use Listing (EUL) is meant to make a vaccine available globally faster, while a WHO prequalification is a global quality tag that ensures vaccines are safe and effective.

The procedures would allow Sputnik V to be included in the list of medical products that meet leading quality, safety and efficacy standards, RDIF CEO Kirill Dmitriev said in a statement.

ADVERTISEMENT

The vaccine, developed by Moscow’s Gamaleya Research Institute and marketed by RDIF, is based on a platform of human adenoviral vectors.

(Reporting by Vishwadha Chander in Bengaluru; Editing by Mark Heinrich)